Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arena Pharmaceuticals has announced that its partner Ortho-McNeil-Janssen Pharmaceuticals has initiated a first-in-human Phase I clinical trial of APD597, a novel oral drug candidate discovered by Arena that targets the glucose-dependent insulinotropic receptor for the treatment of type 2 diabetes.
Subscribe to our email newsletter
Ortho-McNeil’s Phase I program will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of APD597 in single and multiple ascending dose studies in healthy volunteers. Ortho-McNeil’s planned clinical studies will also include the evaluation of patients with type 2 diabetes.
The glucose-dependent insulinotropic receptor (GDIR) was also discovered by Arena and has the potential to stimulate insulin release in response to increases in blood glucose.
Jack Lief, president and CEO of Arena, said: “The GDIR is a promising and exciting target for the treatment of type 2 diabetes. We look forward to continuing to work with Ortho-McNeil on APD597 as it advances in the clinic.”